Filing summary
Entity and period: The supplied filing is a Form 10-Q for Oncobiologics, Inc. (now identified in the request metadata as Outlook Therapeutics), for the quarter ended March 31, 2017, its fiscal second quarter. The filing itself names Oncobiologics, Inc.; investors should verify the entity and any subsequent name change. Financial statements are unaudited.
Business context and reporting period
Oncobiologics was a clinical-stage biosimilar developer with no products approved for sale. Its lead candidates, ONS-3010 (adalimumab/Humira biosimilar) and ONS-1045 (bevacizumab/Avastin biosimilar), had completed Phase 1 trials and were being prepared for Phase 3. Six additional candidates were in preclinical development. Revenue came from collaboration and licensing arrangements, not product sales.
Key financial metrics
| Metric | Three months ended March 31, 2017 | Six months ended March 31, 2017 |
|---|---|---|
| Collaboration revenue | $303,141 | $606,281 |
| Research and development expense | $4.20 million | $17.51 million |
| General and administrative expense | $4.05 million | $8.93 million |
| Operating loss | $7.94 million | $25.84 million |
| Net loss | $8.04 million | $27.14 million |
| Basic net loss per share | $0.34 | $1.16 |
- Cash flow: For the six months, operating cash use was $9.95 million, investing cash use was $0.19 million, and financing provided $7.87 million. Cash fell by $2.27 million to $81,049.
- Liquidity and debt: At March 31, current assets were $0.85 million against current liabilities of $34.78 million. The balance sheet showed $10.0 million face value of senior secured notes, due December 2017, with a $6.61 million carrying value after discount, and $4.61 million of stockholder notes payable on demand. Total liabilities were $44.31 million; stockholders’ deficit was $26.85 million.
- Margins: The filing does not provide a meaningful gross margin; the company had no product sales and reported collaboration revenue.
Changes versus the prior comparable period
- Quarterly collaboration revenue decreased 70% to $0.30 million from $0.99 million; six-month revenue decreased 70% to $0.61 million from $1.99 million. Management attributed the declines to fewer milestone payments and slower recognition of deferred revenue after extending the estimated performance period to December 2021.
- Quarterly net loss widened to $8.04 million from $3.54 million; six-month net loss widened to $27.14 million from $20.41 million.
- Six-month operating cash use improved to $9.95 million from $19.07 million, largely reflecting working-capital movements and noncash items; cash nevertheless ended the period at only $81,049.
- G&A expense comparisons were affected by prior-year negative stock-based compensation expense from remeasurement of performance stock units. Public-company costs also contributed to the increase.
Outlook, risks and unusual items
- Going concern: Management and the filing state that substantial doubt exists about the company’s ability to continue as a going concern. Management expected cash on hand plus April financing proceeds to fund operations only through May 2017; substantial additional financing was needed. Failure to secure funding could force further scaling back or suspension of activities.
- Subsequent financing: On April 13, 2017, the company issued an additional $3.5 million of senior secured notes and warrants. The amended financing agreement permitted up to $1.5 million more in notes and warrants without further holder approval, subject to its terms. The notes bear 5% interest and mature December 22, 2017; they are secured by company assets and subject to restrictive covenants.
- Other financing: A March 2017 Lincoln Park agreement gave the company the right, but not the obligation, to sell up to $15.4 million of shares over 30 months, subject to conditions and ownership limits. The company reported $659,790 of proceeds from additional purchases in April and May.
- Development plans: Management planned to begin Phase 3 programs for ONS-3010 and ONS-1045 in 2018, contingent on partnership funding. The filing says the bulk of Phase 3 work had been postponed pending funding. Regulatory approval, trial results, partnerships, and market acceptance remain uncertain; no formal financial guidance was provided.
- Warrant accounting: Notes-related warrants were classified as a Level 3 liability because of cash-settlement features. Their fair value was $3.86 million at March 31; a $1.04 million quarterly gain from remeasurement reduced the reported loss.
- The company reported effective disclosure controls, no material changes to internal control over financial reporting, and no pending legal matters it believed would materially affect its financial condition or results.
Important facts for investors to verify
- Confirm the issuer identity and relationship between the filing’s Oncobiologics name and the Outlook Therapeutics metadata.
- Verify current cash runway, subsequent financing, debt maturities, security interests, and whether demand stockholder notes have been repaid or extended.
- Check whether additional financing or licensing and co-development agreements were secured, and whether the Lincoln Park facility remained available and usable under its conditions.
- Confirm the status, timing, funding, and regulatory progress of the ONS-3010 and ONS-1045 Phase 3 programs.
- Review the assumptions underlying deferred-revenue recognition and the Level 3 warrant valuation, as well as the substantial stock-based compensation effects on period comparisons.